Nektar Therapeutics
$ 76.48
4.13%
07 Aug - close price
- Market Cap 2,481,584,000 USD
- Current Price $ 76.48
- High / Low $ 77.00 / 73.18
- Stock P/E N/A
- Book Value 19.55
- EPS -7.97
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.54 %
- 52 Week High 109.00
- 52 Week Low 22.28
About
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Analyst Target Price
$153.22
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-12 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-04 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -1.78 | -1.2898 | -1.87 | -2.95 | -3.61 | -0.15 | -2.65 | -2.81 | -2.76 | -0.22 | -2.85 | -4.05 |
| Estimated EPS | -1.48 | -3.495 | -2.79 | -3.13 | -2.82 | -0.13 | -3.09 | -3.01 | -3.07 | -0.21 | -2.4 | -3.3 |
| Surprise | -0.3 | 2.2052 | 0.92 | 0.18 | -0.79 | -0.02 | 0.44 | 0.2 | 0.31 | -0.01 | -0.45 | -0.75 |
| Surprise Percentage | -20.2703% | 63.0959% | 32.9749% | 5.7508% | -28.0142% | -15.3846% | 14.2395% | 6.6445% | 10.0977% | -4.7619% | -18.75% | -22.7273% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.94 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NKTR
2026-08-04 08:43:24
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing by its officers and directors. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to restore investor capital and ensure corporate accountability.
2026-08-03 22:41:14
Nektar Therapeutics has initiated two global Phase 3 trials (ZENITH AD-1 and ZENITH AD-2) for rezpegaldesleukin, targeting moderate-to-severe atopic dermatitis. This move could significantly alter the investment outlook for Nektar, as the success of these trials is crucial for validating its T-reg focused biologic and securing future revenue, despite recent equity offerings causing dilution. The trials amplify both the potential for significant clinical catalysts and the financial risks associated with large, costly late-stage studies.
2026-08-03 15:41:14
Bronstein, Gewirtz & Grossman, LLC is investigating Nektar Therapeutics (NKTR) for potential corporate wrongdoing. The firm encourages investors who purchased Nektar securities before February 26, 2025, and still hold them, to contact them to assist with the investigation. This investigation is being conducted on a contingency fee basis, meaning the firm seeks reimbursement for expenses and fees only if successful.
2026-08-01 06:39:33
This article provides financial data, specifically the "Price to sales forward" for Nektar Therapeutics (NASDAQ:NKTR). The content is minimal, appearing to be a data point or a financial snapshot within a larger financial analysis platform like TradingView. It indicates the value and change of this financial metric, though the specific figures are not provided.
2026-08-01 02:40:46
This article presents financial data for Nektar Therapeutics (NASDAQ: NKTR), specifically focusing on its enterprise value to EBIT forward. The data is provided by TradingView, indicating that the market for NKTR was closed at the time of publication with no trades. The content highlights the financial overview of the company within the health technology and pharmaceuticals sector.
2026-07-31 15:11:36
Vanguard Capital Management has reported a beneficial ownership of 5.17% in Nektar Therapeutics (NKTR) common stock as of June 30, 2026. This stake, totaling 1,747,653 shares, includes holdings in Vanguard funds and managed accounts. Vanguard exercises sole voting power over 250,804 shares and sole dispositive power over all 1,747,653 shares.
